EMA Authorised: Evrysdi (risdiplam) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Evrysdi (risdiplam) for spinal muscular atrophy with accelerated assessment. The decision date was 20 April 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• EVRYSDI (risdiplam)

Snippet

Status: Authorised. Therapeutic area: Muscular Atrophy, Spinal. MAH: Roche Registration GmbH. Decision date: 20/04/2026. Accelerated assessment